Where I see patients (1)
Selected research
-
HER2-low status as a distinct breast cancer subtype: myth or truth? Analysis of the WSG trials WSG-ADAPT-HR+/HER2-, WSG-PlanB, and WSG-ADAPT-TN.
Breast cancer research : BCR
-
Development and Validation of the RSClinN+ Tool to Predict Prognosis and Chemotherapy Benefit for Hormone Receptor-Positive, Node-Positive Breast Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
-
Molecular Characterization of HER2-Low Invasive Breast Carcinoma by Quantitative RT-PCR Using Oncotype DX Assay.
The oncologist
Contact me
- Request appointment
- Refer a patient
- (415) 353-7043